Mylan emerges as victor for Merck KGaA generics business
Mylan struck a deal over the weekend to acquire Merck KGaA’s generics business for $6.7 billion in cash.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.